Sign in Subscribe
Class action lawsuits

MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Misleading Statements

Strategic Insights

— 1 min read

MoonLake Immunotherapeutics, a Swiss clinical-stage biotechnology company, is facing a class action lawsuit alleging that the company misled investors about the efficacy of its drug candidate, SLK. The lawsuit claims that MoonLake made false statements regarding the superiority of SLK over monoclonal antibodies, including its ability to penetrate tissues and demonstrate clinical efficacy. The allegations come after MoonLake announced disappointing week-16 results from its Phase 3 VELA program, which showed that SLK failed to demonstrate competitive efficacy relative to BIMZELX, a FDA-approved drug.

Key Takeaways:

  • MoonLake Immunotherapeutics is facing a class action lawsuit alleging that the company misled investors about the efficacy of its drug candidate, SLK.
  • The lawsuit claims that MoonLake made false statements regarding the superiority of SLK over monoclonal antibodies, including its ability to penetrate tissues and demonstrate clinical efficacy.
  • The allegations come after MoonLake announced disappointing week-16 results from its Phase 3 VELA program, which showed that SLK failed to demonstrate competitive efficacy relative to BIMZELX, a FDA-approved drug.
  • The lead plaintiff must submit their papers to the court by December 15, 2025, to serve as the representative party directing the litigation.
  • Shareholders who wish to participate in the class action lawsuit must submit their papers to the court by December 15, 2025, to be eligible for a recovery.
  • The lawsuit is being led by attorney Aaron Dumas, Jr. of Robbins LLP.

Statistics:

  • MoonLake's stock price fell $55.75 per share, or 89.9%, to close at $6.24 on September 29, 2025.
  • The class period for the lawsuit is March 10, 2024 to September 29, 2025.
  • The Phase 3 VELA program showed that SLK failed to demonstrate competitive efficacy relative to BIMZELX.
  • The lawsuit alleges that MoonLake lacked a reasonable basis for their positive statements regarding SLK's purported superiority to monoclonal antibodies.

Sources:

  • GlobeNewswire press release, "MoonLake Immunotherapeutics Announces Investigation of Misleading Statements Regarding SLK Drug Candidate" (October 17, 2025).
  • Robbins LLP, "Investigation of Misleading Statements Regarding MoonLake Immunotherapeutics MLTX" (October 17, 2025).
  • MoonLake Immunotherapeutics investor presentation (September 28, 2025).

Read more